tDCS (transcranial direct current stimulation)
What studies of tDCS (transcranial direct current stimulation) found
At a glance, by condition
Long COVID: D Little or no difference
Based on the strongest evidence, the placebo trial (low certainty): 2 of 4 findings are D, a tie, so the grade of daily functioning, as the rule below says.
9 outcomes rated · see each below
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 3 findings, all C.
3 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, studies found little or no difference with tDCS (transcranial direct current stimulation). For ME/CFS, tDCS (transcranial direct current stimulation) might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- TDCS (transcranial direct current stimulation) · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- TDCS (transcranial direct current stimulation) · Long COVID is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Anxiety1 study · 10 people received tDCS (transcranial direct current stimulation) Improvement B
Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (30 in all).
The placebo trial30 randomised · nine sessions over three weeks · 2 mA, 20 min, nine sessions over three weeks
Anxiety improved more than in the comparison group.
TDCS (transcranial direct current stimulation) may reduce anxiety in long COVID. Improvement · low certainty B
- Some concerns about bias (RoB 2)
- Few people (30 in all)
See the 1 study
-
- People in the study
- 30 randomised
- Dose
- 2 mA, 20 min, nine sessions over three weeks
- Outcome
- anxiety Beck Anxiety Inventory
- Effect
- better (not tested)
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Sleep1 study · 10 people received tDCS (transcranial direct current stimulation) Improvement B
Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (30 in all).
The placebo trial30 randomised · nine sessions over three weeks · 2 mA, 20 min, nine sessions over three weeks
Sleep improved more than in the comparison group.
TDCS (transcranial direct current stimulation) may improve sleep in long COVID. Improvement · low certainty B
- Some concerns about bias (RoB 2)
- Few people (30 in all)
See the 1 study
-
- People in the study
- 30 randomised
- Dose
- 2 mA, 20 min, nine sessions over three weeks
- Outcome
- daytime sleepiness Epworth Sleepiness Scale
- Effect
- better (not tested)
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Depression1 study · 23 people received tDCS (transcranial direct current stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (23 in all).
Studies with no comparison group47 randomised · 48 started · eight sessions for eight consecutive days over the course of two consecutive weeks, with a break over the weekend between weeks · 2 mA, 20 min/day, eight sessions for eight consecutive days over the course of two consecutive weeks, with a break over the weekend between weeks
Depression improved.
The evidence is very uncertain about the effect of tDCS (transcranial direct current stimulation) on depression in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (23 in all)
See the 1 study
-
- People in the study
- 47 randomised · 48 started
- Dose
- 2 mA, 20 min/day, eight sessions for eight consecutive days over the course of two consecutive weeks, with a break over the weekend between weeks
- Outcome
- BDI-II Beck depression inventory
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people, or how many isn't reported; not all results were tested against chance.
Studies with no comparison group1 study (few people)
Low mood or anxiety improved.
The evidence is very uncertain about the effect of tDCS (transcranial direct current stimulation) on low mood or anxiety in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people, or how many isn't reported
- Not all results were tested against chance
See the 1 study
-
- People in the study
- —
- Dose
- —
- Outcome
- emotional complaints (A-PASC inventory)
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)6 studies · 89 people received tDCS (transcranial direct current stimulation) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); 210 people in all; a small benefit can't be ruled out; the studies disagree.
Randomised trials5 studies · 210 people with results
No clear difference in cognition (brain fog).
The evidence is very uncertain about the effect of tDCS (transcranial direct current stimulation) on cognition (brain fog) in long COVID. Little or no difference · very low certainty D
- Some concerns about bias (RoB 2)
- 210 people in all; a small benefit can't be ruled out
- The studies disagree
Studies with no comparison group1 study (few people)
Cognition (brain fog) improved.
The evidence is very uncertain about the effect of tDCS (transcranial direct current stimulation) on cognition (brain fog) in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people, or how many isn't reported
- Not all results were tested against chance
See the 6 studies
-
- People in the study
- 42 randomised · 41 started · 40 analysed
- Dose
- 1.5 mA, 30 minutes per session, four consecutive daily sessions
- Outcome
- behavioral state fatigue markers
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
-
- People in the study
- 47 randomised · 48 started
- Dose
- 2 mA, 20 min/day, eight sessions for eight consecutive days over the course of two consecutive weeks, with a break over the weekend between weeks
- Outcome
- Stroop (IG) Stroop Color-Word Interference test
- Effect
- no clear difference
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
-
- People in the study
- 33 randomised
- Dose
- 2mA, 20 tDCS sessions, lasting 30min
- Outcome
- cognition
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
-
- People in the study
- 30 randomised
- Dose
- 2 mA, 20 min, nine sessions over three weeks
- Outcome
- global cognition Addenbrooke's Cognitive Examination-Revised
- Effect
- better (not tested)
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial (2026) preprint
- People in the study
- 60 randomised
- Dose
- 2 mA for 20 minutes, concurrently with the CT or PMR interventions, with simultaneous onset
- Outcome
- N-back task performance (untrained working memory), primary outcome, CT vs PMR at post-intervention
- Effect
- no clear difference
- Risk of bias
RoB 2: Low
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
-
- People in the study
- —
- Dose
- —
- Outcome
- cognitive complaints (A-PASC inventory)
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue3 studies · 79 people received tDCS (transcranial direct current stimulation) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; 120 people in all; a small benefit can't be ruled out.
Placebo trials3 studies · 120 people with results
No clear difference in fatigue.
The evidence is very uncertain about the effect of tDCS (transcranial direct current stimulation) on fatigue in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- 120 people in all; a small benefit can't be ruled out
Combination: tDCS (transcranial direct current stimulation) + Walking9 in the study
Transcranial direct current electrical stimulation in combination with aerobic exercise is effective in reducing fatigue and pain in post-COVID-19 systemic autoimmune rheumatic patients (2021): MFIS physical domains, no clear difference.
Shown, not counted: tDCS (transcranial direct current stimulation) was given together with other treatments.
See the 3 studies
-
- People in the study
- 47 randomised · 48 started
- Dose
- 2 mA, 20 min/day, eight sessions for eight consecutive days over the course of two consecutive weeks, with a break over the weekend between weeks
- Outcome
- MFIS-total mean reduction at the end of treatment modified fatigue impact scale
- Effect
- no clear difference
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
-
Same trial, also reported in: Transcranial direct current stimulation in affecting neuropsychiatric symptoms of post-COVID syndrome: No change in microstates and functional connectivity. (2026) (change in fatigue measured by Fatigue impact scale (FIS))
- People in the study
- 35 randomised · 33 started · 33 analysed
- Dose
- DC of 2 mA intensity (current density 0.08 mA/m2), A total of 20 tDCS sessions (Monday to Friday) were administered to patients over a four-week period
- Outcome
- FIS total score change from baseline to week 4 Fatigue Impact Scale
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- High
- Deviations from intended interventions
- Low
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
Same trial, also reported in: Modulating subjective and objective cognitive state fatigue in long COVID with repetitive anodal tDCS: results from a double-blinded randomized controlled trial. (2026) (subjective state fatigue)
- People in the study
- 40 randomised
- Dose
- 1.5mA, four consecutive daily sessions of either 30 minutes active (1.5mA) or sham stimulation
- Outcome
- MFIS cognitive subscore Modified Fatigue Impact Scale
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
Daily life and health overall
Daily functioning1 study · 20 people received tDCS (transcranial direct current stimulation) Little or no difference D
Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 60 people found no clear difference; a small benefit can't be ruled out.
The placebo trial60 randomised · nine 20-minute intervention sessions over three weeks · 2 mA for 20 minutes, concurrently with the CT or PMR interventions, with simultaneous onset
No clear difference in daily functioning.
TDCS (transcranial direct current stimulation) may make little or no difference to daily functioning in long COVID. Little or no difference · low certainty D
- One trial of 60 people found no clear difference; a small benefit can't be ruled out
Combination: tDCS (transcranial direct current stimulation) + Walking9 in the study
Transcranial direct current electrical stimulation in combination with aerobic exercise is effective in reducing fatigue and pain in post-COVID-19 systemic autoimmune rheumatic patients (2021): timed-up-go-test, better.
Shown, not counted: tDCS (transcranial direct current stimulation) was given together with other treatments.
See the 1 study
-
Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial (2026) preprint
- People in the study
- 60 randomised
- Dose
- 2 mA for 20 minutes, concurrently with the CT or PMR interventions, with simultaneous onset
- Outcome
- Functional status (Post-COVID Functional Status Scale), CT vs PMR Post-COVID Functional Status Scale
- Effect
- no clear difference
- Risk of bias
RoB 2: Low
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
Quality of life1 study · 20 people received tDCS (transcranial direct current stimulation) Little or no difference D
Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 60 people found no clear difference; a small benefit can't be ruled out.
The placebo trial60 randomised · nine 20-minute intervention sessions over three weeks · 2 mA for 20 minutes, concurrently with the CT or PMR interventions, with simultaneous onset
No clear difference in quality of life.
TDCS (transcranial direct current stimulation) may make little or no difference to quality of life in long COVID. Little or no difference · low certainty D
- One trial of 60 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial (2026) preprint
- People in the study
- 60 randomised
- Dose
- 2 mA for 20 minutes, concurrently with the CT or PMR interventions, with simultaneous onset
- Outcome
- Health-related quality of life (PROPr score), CT vs PMR PROMIS-Preference (PROPr) score
- Effect
- no clear difference
- Risk of bias
RoB 2: Low
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
Overall symptoms1 study · 16 people received tDCS (transcranial direct current stimulation) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 33 people found no clear difference; a small benefit can't be ruled out.
The placebo trial35 randomised · 33 started · 33 analysed · over a four-week period · DC of 2 mA intensity (current density 0.08 mA/m2), A total of 20 tDCS sessions (Monday to Friday) were administered to patients over a four-week period
No clear difference in overall symptoms.
The evidence is very uncertain about the effect of tDCS (transcranial direct current stimulation) on overall symptoms in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 33 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 35 randomised · 33 started · 33 analysed
- Dose
- DC of 2 mA intensity (current density 0.08 mA/m2), A total of 20 tDCS sessions (Monday to Friday) were administered to patients over a four-week period
- Outcome
- A-PASC total score change, active vs sham Post-COVID-19 Symptoms Assessment Questionnaire
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- High
- Deviations from intended interventions
- Low
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
ME/CFS
Symptoms
Cognition (brain fog)1 study · 1 (few people) person received tDCS (transcranial direct current stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · 14 months after initial presentation · 2 mA/min, 20 minutes, 40 mA total dose, daily; after four weeks twice daily (few people)
Cognition (brain fog) improved.
The evidence is very uncertain about the effect of tDCS (transcranial direct current stimulation) on cognition (brain fog) in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- 2 mA/min, 20 minutes, 40 mA total dose, daily; after four weeks twice daily
- Outcome
- omission errors (selective attention)
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning1 study · 1 (few people) person received tDCS (transcranial direct current stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · 14 months after initial presentation · 2 mA/min, 20 minutes, 40 mA total dose, daily; after four weeks twice daily (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of tDCS (transcranial direct current stimulation) on daily functioning in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- 2 mA/min, 20 minutes, 40 mA total dose, daily; after four weeks twice daily
- Outcome
- full recovery with improved exercise tolerance and return to physical exercise
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person received tDCS (transcranial direct current stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · 14 months after initial presentation · 2 mA/min, 20 minutes, 40 mA total dose, daily; after four weeks twice daily (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of tDCS (transcranial direct current stimulation) on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- 2 mA/min, 20 minutes, 40 mA total dose, daily; after four weeks twice daily
- Outcome
- full clinical recovery
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
Stopping because of side effects2 studies
No participants discontinued prematurely due to postexertional malaise
Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial. (2026)No serious AE were reported and no participant discontinued the intervention due to AE.
Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial (2026)
Side effects studies reported5 kinds
| Side effect | Studies that reported it |
|---|---|
| Dizziness | 2 studies |
| Headache | 2 studies |
| Trouble sleeping | 2 studies |
| Nausea or stomach upset | 1 study |
| Worse symptoms or a flare | 1 study |
All papers
- Modulating subjective and objective cognitive state fatigue in long COVID with repetitive anodal tDCS: results from a double-blinded randomized controlled trial.2026 · placebo trial · 42 randomised · 41 started · 40 analysed
Summary
This double-blind randomised controlled trial in Magdeburg, Germany, asked whether four consecutive daily sessions of 30-minute anodal tDCS over the left dlPFC could change cognitive state fatigue in long COVID. Of 42 people recruited, 41 were randomly assigned and 40 were analysed (verum n=20; sham n=20). Verum tDCS was 1.5 mA, with a gamified Go/No-Go task during stimulation; the comparator was sham tDCS with the same ramp-up and ramp-down. Assessments before, after and one month later measured subjective state fatigue with visual analogue scales, behavioural performance on the AX-CPT, frontal theta and occipital alpha EEG power, p50 sensory gating, and Go/No-Go performance. The paper reports no significant effect of stimulation on subjective state-fatigue ratings or behavioural performance. For occipital alpha, post hoc comparisons showed a stronger increase at post-assessment in the sham group than the verum group (mean difference 0.06, p=0.011), and a reduction in alpha increase from post-assessment to follow-up in the sham group (mean difference 0.05, p=0.010). Frontal theta showed no significant stimulation effect. p50 showed a trend-level time × stimulation interaction (p=0.056), with a before-after AX-CPT difference in the sham group (mean difference 29.90, p=0.010) but not the verum group. Side-effect reports included tingling in 80% with verum and 45% with sham, and skin redness in 60% and 10%. Withdrawals for harms were not reported. The authors state limits including powering for the primary outcome, insensitive behavioural measures, and modest sample size.
- Cognitive fatigue in long COVID : a multimodal perspective on subjective and objective markers and their modulation via transcranial direct current stimulation2026 · placebo trial · 40 randomised
Summary
This dissertation examined cognitive fatigue in long COVID and its modulation with transcranial direct current stimulation (tDCS). Project B included 40 long COVID patients who underwent four sessions of anodal tDCS of the left dorsolateral prefrontal cortex in a preregistered, randomized, double-blind, sham-controlled study. Project C also involved a preregistered, double-blind, randomized, sham-controlled study, including 29 sessions of self-administered home-based tDCS. Fatigue was assessed with subjective, behavioural, electrophysiological and immunological measures. Cognitive trait fatigue decreased after both anodal and sham stimulation, with no between-group difference reported. Interim analyses in project C revealed a beneficial effect of tDCS on subjective fatigue, which persisted up to one month post-intervention. For harms, the paper states: 'tDCS was well tolerated and safe.' Side-effect counts, withdrawals for harms, the number analysed, the setting, and where patients came from were not reported. The authors conclude: 'The findings underscore the complexity of fatigue assessment, the need for multimodal approaches and the promise of neuromodulation as a supportive treatment strategy.' Limitations were not reported in the abstract.
- Prefrontal transcranial direct current stimulation combined with cognitive training reduces anxiety, daytime sleepiness, and cognitive complaints in women after COVID-19: A randomized, double-blind, sham-controlled trial.2026 · placebo trial · 30 randomised
Summary
This single-centre, randomized, double-blind, sham-controlled trial examined adding left-prefrontal transcranial direct current stimulation (tDCS) to cognitive training in 30 women with confirmed prior COVID-19 and self-reported cognitive decline. Participants were allocated to three groups (n = 10 each): cognitive training plus active tDCS, cognitive training plus sham tDCS, or cognitive training only. Active tDCS targeted the left dorsolateral prefrontal cortex at 2 mA for 20 min (anode F3, return F7) across nine sessions over three weeks. Anxiety (Beck Anxiety Inventory), daytime sleepiness (Epworth Sleepiness Scale), cognition (Addenbrooke's Cognitive Examination-Revised), reaction times, and prefrontal EEG markers were assessed at baseline and after the ninth session; there was no follow-up. Relative to both comparison groups, the CT + tDCS group showed significantly lower anxiety and daytime sleepiness and higher global cognition, memory, and fluency, with faster reaction times (all corrected p; exact value not reported), with parallel changes in prefrontal EEG markers. All participants completed the trial (no dropout); harms were not reported. The authors state that confirmation in larger samples is needed.
- Transcranial direct current stimulation in affecting neuropsychiatric symptoms of post-COVID syndrome: No change in microstates and functional connectivity.2026 · placebo trial · 35 randomised · 33 started · 26 analysed
Summary
This randomised, sham-controlled trial asked whether tDCS changes EEG microstates and functional connectivity in post-COVID syndrome. Out of 71 screened people, 35 met inclusion criteria; 33 started (16 active, 17 sham) and 26 were analysed (13 active, 13 sham). Participants received 20 tDCS sessions over four weeks, five times per week, 30 min each at 2mA with anode F3 and cathode F4; the sham group had a 30s ramp-up and immediate ramp-down followed by 29 min rest. Resting-state EEG was recorded at baseline, after two weeks, and after four weeks. The paper reports no significant results for microstate parameters or functional connectivity between F3 and F4; the authors also report no significant change in clinical status or EEG parameters. No serious adverse events were noted; minor adverse events were expected (e.g., tingling or burning sensation) and did not influence participants’ capability to continue. There were no missed sessions. The authors state the EEG endpoints were exploratory and the study was primarily powered for clinical results; they write that small effects cannot be excluded with limited statistical power. They also note the study was performed at a single geographical location with a fairly homogenous population.
- Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial2026 · placebo trial · 60 randomised · preprint
- Evaluating the efficacy of repetitive anodal transcranial direct current stimulation on cognitive fatigue in long COVID: A randomized controlled trial.2025 · placebo trial · 40 randomised
Summary
This randomized, double-blind, sham-controlled trial enrolled 40 long COVID patients with cognitive fatigue. Participants received four consecutive daily sessions of either 30 minutes active anodal tDCS at 1.5mA over the left dorsolateral prefrontal cortex or sham stimulation. Assessments occurred before treatment, one day post-treatment, and at a one-month follow-up. The primary outcome was the Modified Fatigue Impact Scale (MFIS) cognitive subscore; assessments also included depressive symptoms and quality of life. The results revealed significant improvements in MFIS cognitive scores for both the active and sham stimulation groups, with benefits lasting up to one month. The study did not reveal stimulation-specific effects on subjective cognitive fatigue. Across all participants, subjective trait fatigue ratings fell from pre- to post-assessment (mean difference = 2.38, p < .001) and from pre-assessment to follow-up (mean difference = 3.35, p < .001); the post-assessment to follow-up reduction was non-significant (mean difference = 0.98, p = .095). Depressive symptom ratings fell from pre- to post-assessment (mean difference = 1.6, p = .003) and to follow-up (mean difference = 2.0, p < .001), and remained stable from post-assessment to follow-up (mean difference = 0.4, p = .428). EQ-5D-5L health scale ratings increased from pre-assessment to follow-up (mean difference = − 5.40, p = .046); health index ratings increased pre-to-post (mean difference = − 0.09, p = .003) and pre-to-follow-up (mean difference = − 0.07, p = .010). During the four stimulation sessions, participants experienced minimal side effects, and no significant adverse events were reported. Withdrawals were not reported.
- Transcranial direct current stimulation (tDCS) in the treatment of neuropsychiatric symptoms of long COVID.2024 · placebo trial · 35 randomised · 33 started · 33 analysed
- Design and Evaluation of a Potential Non-Invasive Neurostimulation Strategy for Treating Persistent Anosmia in Post-COVID-19 Patients.2023 · placebo trial · 25 randomised · 15 started
Summary
This study asked whether transcranial direct current stimulation (tDCS) could treat persistent anosmia after COVID-19. Twenty-five patients were recruited from July 2021 to February 2022 (12 females/13 males, aged 19 to 55 years); 15 participated in the neurostimulation evaluation. Participants were randomly divided, with stratification by gender, into active tDCS (0.5 mA) or sham, with five sessions on different days within a maximum of two weeks; the olfactory test was repeated less than two weeks after the last stimulation session. Smell was measured with threshold, discrimination and identification (TDI) scores. In the anosmic active group, mean TDI was 15.38±0.18 initially and 17.00±1.41 at the final test; in the hyposmic active group it was 26.96±5.3 initially and 25.75±3.25 finally; the sham group had final and initial scores of 27.68±6.79 and 27.68±3.93. The authors report that the evolution across all groups did not reach statistical significance, and that some patients declined to continue, reducing the stimulation sample from 20 to 15.
- Transcranial direct current stimulation for post-COVID fatigue: a randomized, double-blind, controlled pilot study.2023 · placebo trial · 47 randomised · 48 started
Summary
This double-blind, parallel-group, sham-controlled pilot study at Hospital Clínico San Carlos, Madrid, included patients with post-COVID syndrome and chronic fatigue. Forty-eight patients were randomly assigned; 47 were analysed (23 active tDCS, 24 sham). Active treatment was anodal transcranial direct current stimulation over the left dorsolateral prefrontal cortex at 2 mA for 20 min/day, eight sessions over two consecutive weeks, compared with sham tDCS. Assessments at baseline, immediately after the last session, and one month later used the modified fatigue impact scale (MFIS), Stroop test, Beck depression inventory (BDI-II) and EuroQol-5D. For MFIS-physical, the time-by-group interaction (P = 0.034) and group effect (P = 0.026) were significant; the active group improved from baseline at the end of treatment (mean difference 0.105, P < 0.001) and at one month (mean difference 0.085, P = 0.001), while the sham group did not. For MFIS-total, the interaction was not significant (P = 0.184); mean reductions were 9.8 points with active and 7.7 with sham. No significant effects were reported for MFIS-cognitive, MFIS-psychosocial or Stroop. BDI-II showed a significant time-by-group interaction (P = 0.036); EuroQol-5D showed no significant interaction (P = 0.120). Adverse events were reported by 4 active (17.39%) and 5 sham (20.83%) patients; headache in 3 active and 4 sham, dizziness in 1 each; all were mild, and no severe adverse events were observed. One active patient discontinued after the first session due to personal issues.
- Non-invasive brain stimulation for fatigue in post-acute sequelae of SARS-CoV-2 (PASC).2023 · placebo trial · 70 randomised
Summary
This randomized, double-blind, sham-controlled trial (NCT05289115) enrolled 70 patients with PASC-related fatigue followed in an outpatient clinic. Participants received active HD-tDCS (3 mA targeting the left primary motor cortex for 30 min) or sham HD-tDCS, each paired with a rehabilitation program, for 10 sessions (2 sessions/week) over five weeks; 35 patients were in each group. At the end of the five-week intervention, the active group had a greater reduction in MFIS total fatigue (mean group difference 14.03 points; 95% CI 7.78–20.28; P < .001). MFIS cognitive (mean group difference 8.29 points) and psychosocial (2.37 points) favored active; physical fatigue did not differ (0.71 points; P = .09). Anxiety (HAM-A) favored active (4.88), quality of life (WHOQOL-bref) favored active (14.80), and pain did not differ (−0.74; P = .09). The proportion of clinically improved participants was 77.14% vs 45.71% (NNT = 3; odds ratio = 0.24). Skin redness occurred 37 times in the active group vs 13 in the sham group (P < .001); no serious adverse events were reported.
- Treatment of cognitive symptoms in post-COVID-19 syndrome – a transcranial direct current stimulation (tDCS) approach2023 · placebo trial · 34 randomised · 15 analysed
Summary
This four-week, double-blind, randomized, placebo-controlled, parallel study examined active dorsolateral prefrontal cortex (DLPFC) tDCS versus sham tDCS in patients with post-COVID-19 syndrome / PASC and cognitive symptoms. The active arm received 20 tDCS applications (anode on the F3; 2 mA, 30 min/tDCS session). Patients were evaluated at baseline, after two weeks, and at the end of four weeks of treatment with tests of attention (digit span forward), working memory (digit span backward), and psychomotor speed (digit symbol substitution test). Of 34 enrolled patients, 15 were included in the Intention-to-treat (ITT) analysis. The paper reports no significant difference in cognitive tests results between active DLPFC tDCS and sham tDCS after four weeks. It also states that no major side effects were observed during and after the treatment. The authors note that the study is still in progress and the results will be updated. The study was supported by grant No. NU22-D-133 of the MH CR.
- Transcranial Direct Current Stimulation (tDCS) in the treatment of neuropsychiatric symptoms of Post-Covid syndrome2022 · placebo trial · 35 randomised · 33 started · 26 analysed
Summary
This randomised two-arm sham-controlled trial enrolled 35 participants who met inclusion criteria from 71 screened; 33 started the intervention (n = 16 active, n = 17 sham), and 26 were included in the EEG analyses (n = 13 active, n = 13 sham). Participants had post-COVID syndrome with neuropsychiatric symptoms, including fatigue or brain fog for > 1 month after PCR-confirmed COVID-19, and the study was performed at a single geographical location. Active treatment was tDCS (anode over F3, cathode over F4; 2mA; current density 0.08mA/cm2) for 20 sessions over four weeks, 30 min each, five times per week, with the first session at the clinic and subsequent sessions self-administered at home. Sham tDCS used a 30s ramp-up, immediate ramp-down, and 29 min of rest. Resting-state EEG was measured at baseline, after two weeks, and after four weeks; microstates and functional connectivity between F3 and F4 were analysed. The paper reports no significant results. No serious adverse events were noted; minor adverse events were expected (e.g., tingling or burning sensation) and did not influence participants’ capability to continue. Two participants withdrew consent before the intervention. Reasons for not performing EEG analysis included not attending EEG measurement (n = 3) and insufficient EEG data after artefact rejection and pre-processing (n = 4). Clinical and cognitive outcomes are described in a separate article.
- Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial.2026 · randomised trial · 328 randomised · 320 started
Summary
This 5-arm, multicenter randomized trial asked whether remotely delivered rehabilitation strategies improve cognitive symptoms in people with cognitive long COVID. It enrolled 328 participants at 22 trial sites in the US; 320 received at least 1 intervention. Over 10 weeks, participants were assigned to adaptive online BrainHQ, PASC-CoRE (9 90-minute group sessions and 3 30-minute individual sessions) plus BrainHQ, active tDCS (2.0 mA for 30 minutes) plus BrainHQ, an active comparator of online puzzles and games, or sham tDCS plus BrainHQ, with interventions 5 times per week. The primary outcome was the modified ECog2 at the end of intervention. There were no differences on the modified ECog2 for any prespecified primary treatment comparison in the ITT population (N = 328); adjusted differences were 0.0 (95% CI, −0.2 to 0.2) for BrainHQ vs active comparator, 0.1 (−0.1 to 0.3) for PASC-CoRE + BrainHQ vs active comparator, 0.0 (−0.2 to 0.2) for tDCS-active + BrainHQ vs tDCS-sham + BrainHQ, and 0.1 (−0.1 to 0.3) for PASC-CoRE + BrainHQ vs BrainHQ alone. At EOI, the modified ECog2 improved in the range of approximately half an SD in all study arms; secondary outcomes showed no differential benefits. On the overall-functioning item, 4/300 (1.3%) reported much worse and 16/300 (5.3%) somewhat worse; 222/299 (74.2%) said the intervention helped cognitive functioning. At EOI, 143 participants (56%) reported postexertional malaise; no participants discontinued prematurely due to postexertional malaise. In the modified ITT population (n = 320), 11 participants experienced treatment-emergent serious adverse events; there were no serious adverse events attributable to the interventions, and one participant receiving active tDCS reported a minor thermal injury. Limitations included uncertainties about the pathobiology and possible unexpected therapeutic benefits from the active comparator.
- Transcranial direct current stimulation plus cognitive training for cognitive symptoms in patients with post-acute sequelae of SARS-CoV-2 infection: A randomized, double-blind, sham-controlled trial.2025 · randomised trial · 60 randomised · 52 analysed
Summary
This randomized, double-blind, sham-controlled trial enrolled 60 adults aged 18–75 with confirmed SARS-CoV-2 infection within the past six months and persistent cognitive complaints (PASC/long COVID) at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo Medical School, Brazil; participants were recruited via social media and prescreened with proof of a positive RT-PCR or antigen test. Participants were randomized to active tDCS (2 mA anodal-left, cathodal-right prefrontal stimulation) plus app-based cognitive training or sham tDCS plus cognitive training, for a 4-week in-person intervention of 20 weekday sessions. Primary outcomes were six standardized neuropsychological tests at baseline and post-intervention; depression and anxiety were secondary. Sixty participants were randomized (30 per group), and 52 finished the study (26 per arm in the endpoint table). Active tDCS + CT showed significantly greater improvement than sham + CT in inhibitory control (p = 0.046), processing speed (p = 0.034), and divided attention (p = 0.039); other cognitive tests did not show significant group × time interactions. Both groups improved in depressive and anxiety symptoms, with no significant time × group interactions. The paper does not report side effects or withdrawals attributed to harms. The authors state limitations including no correction for multiple comparisons, only a sham control, a combined design that cannot separate tDCS from CT, and possible ceiling/test-retest effects.
- Evaluation of microstates and functional connectivity after transcranial direct current stimulation in post-covid syndrome2025 · randomised trial · 33 randomised
- A randomized comparative feasibility study of neuromodulation and cognitive training for post-COVID fatigue.2025 · randomised trial · 67 randomised · 63 analysed
Summary
In post-COVID condition, this randomized, parallel trial in Madrid compared tDCS over M1 plus cognitive training (M1 + CT) with tDCS over DLPFC plus cognitive training (DLPFC + CT). Sixty-seven participants were recruited; sixty-three completed treatment. Per-arm completed counts conflicted: abstract 32 M1 + CT/31 DLPFC + CT; table 31 M1 + CT/32 DLPFC + CT. Treatment was 15 sessions, 1 session/day, 20 min/session, Monday to Friday, with 2 mA tDCS and adaptive cognitive training. Assessments were at baseline, post-treatment, and one-month follow-up. The primary endpoint, the Fatigue Severity Scale (FSS), showed a significant time effect but no significant time-by-group interaction (F = 1.784, p = 0.172); post-hoc baseline-to-post-treatment mean difference was 5.984 (pbonf < 0.001) and baseline-to-follow-up 6.016 (pbonf < 0.001). Ecological physical fatigue showed a time-per-group effect (F = 4.099; pbonf = 0.050), with M1 + CT t = 4.672 (pbonf < 0.001) and DLPFC + CT t = 1.983 (p = 0.208). Sleep quality showed a time-by-group interaction (p = 0.047), indicating greater improvement in M1 + CT (mean difference = 2.800, pbonf < 0.001). No significant time-by-group interaction was found in any cognitive test. Adverse effects were reported by 14.28%; 7.9% reported headache and 6.34% dizziness; side effects were 6% in M1 + CT and 7% in DLPFC + CT. Among those who declined to continue, two were reinfected with COVID-19, one had scheduling incompatibility with work, and another did not tolerate the CT. The authors state limitations including absence of a control group, one-month follow-up, and small sample size.
- Transcranial direct current stimulation in neuropsychiatric symptoms of post-covid syndrome: No changes in microstates and functional connectivity2024 · randomised trial · 33 randomised
Summary
This randomized two-arm sham-controlled trial enrolled 33 people with post-covid syndrome (PCS) who received tDCS at home: 16 in an active group and 17 in a sham group. Active tDCS was 20 sessions, each lasting 30 min, at 2 mA, with electrodes at F3-F4; the sham group also had 20 sessions lasting 30 min. Resting-state EEG was recorded before tDCS, after 2 weeks and after 4 weeks, and clinical, quality-of-life, fatigue, depressive, anxiety and cognitive measures were assessed. For microstates, no significant difference was found between active and sham groups in baseline:2-weeks and baseline:4-weeks change. For functional connectivity, no significant difference was found after two weeks (T of -0.57, p = 0.58) or after four weeks (T of -0.75, p = 0.46). No significant change was observed in clinical and cognitive status. Reported adverse effects included tingling and burning sensation; no serious adverse events were reported. The number analysed and withdrawals were not reported.
- Transcranial Direct Current Stimulation and Post-COVID-19-Fatigue2021 · randomised trial · 12 randomised
Summary
Twelve subjects with Post-COVID-19-Fatigue were randomly assigned to receive tDCS (4 mA) or sham (n = 6 per group) over the primary motor cortex in four daily 20 min sessions. The study measured subjective fatigue with the FAS and FSS, subjective health with VAS-Health, pain with VAS-Pain, quality of life with the EQ-5D Utility score, objective performance fatigability with isokinetic fatigue indices, and glucose metabolism with FDG-PET before and after stimulation. For pre- to post-intervention changes, the tDCS group experienced a significant decrease in subjective fatigue (FAS; p = 0.04) and an improvement in subjective health (VAS-Health; p = 0.03). The other subjective fatigue (FSS), pain (VAS-Pain), QoL (EQ-5D Utility score), and objective isokinetic fatigue index measures were unchanged (p > 0.09). For the sham group, none of the variables changed significantly (p > 0.06). FDG-PET scans revealed decreased relative FDG uptake after tDCS in several brain regions and increased relative FDG uptake in others. Side effects and withdrawals were not reported. The authors state that perceptions of fatigue and QoL, but not objective performance fatigability, play a prominent role in Post-COVID-19-Fatigue and that tDCS might alter cerebral FDG uptake in fatigue-related brain regions in these patients. Limitations are not reported.
- tDCS improves perceptions of fatigue in patients with Post-COVID-19-symptoms that are less than 6 months post-infection2023 · compared with another group
Summary
This study asked whether symptom severity differs in people with post-COVID-19 fatigue who were ≤ 6 months versus ≥ 6 months post-COVID-19 infection, and whether four consecutive daily sessions of 4 mA or sham tDCS over the motor cortex (M1) change perception of fatigue. Participants were people with post-COVID-19 fatigue; the text reports N = 11 for the ≤ 6 months group and N = 9 for the ≥ 6 months group, but does not report where they came from. The groups were ≤ 6 months/4 mA tDCS, ≤ 6 months/sham, ≥ 6 months/sham, and ≥ 6 months/4 mA tDCS. Outcomes were the Fatigue Severity Scale (FSS), Fatigue Assessment Scale (FAS), and EQ-5D-5L Visual Analog Scale for Health (EQ-5D-5L VAS). In the ≤ 6 months/4 mA tDCS group, FSS decreased from pre 5.46 to post 4.86 (p = 0.01), FAS decreased from pre 32.14 to post 27.57 (p = 0.03), and VAS increased from pre 64.86 to post 75.92 (p = 0.03). The abstract states there were no significant differences in the other groups (≤ 6 months/sham, ≥ 6 months/sham, ≥ 6 months/4 mA tDCS; all p ≥ 0.051). The text does not report side effects or withdrawals. The authors suggest post-COVID-19 symptoms are most severe within 6 months post-COVID-19 infection and that 4 mA tDCS over M1 may decrease perceived fatigability in people with post-COVID-19 fatigue that are less than 6 months post-COVID-19 infection. The text does not state limitations.
- Efficacy of transcranial direct current stimulation and cognitive training for the neurocognitive symptoms of long covid-192023 · no comparison group
Summary
This conference abstract from a research group working on transcranial direct current stimulation (tDCS), a mild electrical brain stimulation through the scalp, reports early findings for people with long COVID who had problems with thinking and memory. It reports preliminary results from a pilot study in which people were given tDCS, without saying how many took part, how many sessions they had, or whether there was a comparison group. In that pilot, people reported fewer thinking and emotional complaints on the A-PASC inventory. On memory tests they did better at remembering word lists straight away and later. There were improving trends, not clearly stated as significant, in word knowledge, word fluency, sustained attention, processing speed and executive function (self-control, mental flexibility and time management). No numbers, p-values or side effects are given. Based on this, the group is now running a pilot randomised trial comparing real tDCS with sham (fake) tDCS, both combined with online cognitive training using the BrainHQ platform with daily sessions. Results of that trial are not reported here.
- Potential application of brain-gut axis-based treatments in Long COVID and ME/CFS: a case-based systematic review.2026 · case report · 1 in the study
Summary
This case report and literature review describes one 33-year-old man with post-COVID ME/CFS admitted to Jaseng Hospital of Korean Medicine. He received vagal reflex stimulation via electroacupuncture of the deep peroneal nerve for 12 weeks (once daily for three consecutive weeks during hospitalization, then tapering). There was no comparison group. Fatigue was assessed with the Multidimensional Fatigue Inventory (total score 20–100) at baseline and at 4, 8 and 12 weeks, and flu-like symptom duration was self-recorded daily. Total MFI score declined from 71 to 31 (a reduction of more than 50%). General fatigue and reduced activity each fell −9 points; mental fatigue improved 63.6% (11 to 4) and reduced motivation 61.5% (13 to 5). General fatigue fell below the cut-off (< 13) at week 8 and reduced activity reached the threshold (< 10) at week 12. Daily flu-like symptom duration decreased from 557.1 ± 51.2 to 17.1 ± 15.8 min. Fluctuations at weeks 4 (282.9 ± 126.0 min) and 8 (285.7 ± 140.5 min) reflected transient, single-day symptom flares. No adverse events were observed. The authors state that lack of follow-up data precluded assessment of treatment durability, objective measures were not obtained, and few RCTs with small samples were included.
- Proceedings #19. Maintenance tDCS: A Case of Full and Durable Recovery from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)2017 · case report · 1 in the study
Summary
This conference proceeding reports a case report of one 61-year-old man with treatment-resistant progressive ME/CFS who was referred for neuromodulation. There was no comparison group. He was trained in the office and then self-administered tDCS at home daily, with anode on the left dorsolateral prefrontal cortex, cathode on the right dorsolateral prefrontal cortex, 2 mA/min, 20 minutes, 40 mA total dose, using 1.5” diameter electrode pads. After four weeks, sessions were increased to twice daily (6 AM and 12 Noon). Modafinil 200 mg provided partial relief of fatigue; later the dose was lowered to 100 mg due to insomnia, and modafinil was stopped but resumed at 100 mg daily after he felt less well. The paper reports one year of maintenance tDCS and follow-up neurophysiological studies 14 months after initial presentation. It reports significant benefit early in the day during the first month of daily tDCS, consistent benefit after twice-daily sessions, and full clinical recovery over the next few months, with improved exercise tolerance and a return to physical exercise several times each week. Before treatment, omission errors were 14.29%; after treatment, behavioral measures were within the normal rage and there were no omission errors. The patient reported sustained relief. The authors state that data were not shown for frontocentral infra-slow frequency drift.
- Effects of high-definition transcranial direct current stimulation combined with inspiratory muscle training for treating respiratory sequelae of long COVID: A case series.2024 · combination: given with other treatments · 6 in the study
Summary
This case series treated six adults, four women and two men aged 29 to 71, who had breathing problems after COVID (long COVID). Each received high-definition transcranial direct current stimulation (HD-tDCS, a mild electrical current to the brain through the scalp) together with inspiratory muscle training, twice a week for 5 weeks. Lung function and breathing-muscle strength were measured at the start and after 5 weeks. The abstract gives no measured results and no side effects; the authors suggest that HD-tDCS may add to the effects of the muscle training. There was no comparison group.
- Teleintervention for Persisting Symptoms Post-Acute COVID-19 Illness Using Transcranial Direct Current Stimulation (tDCS) (P18-6.001)2022 · combination: given with other treatments · 2 in the study · abstract
Summary
Two women aged 42 and 57 with Post-Acute Sequelae of SARS-CoV-2 (PASC), seen 7 and 9 months after acute COVID-19 illness at a clinical transcranial direct current stimulation (tDCS) telehealth service at NYU Langone Health, received daily at-home tDCS sessions delivered via video visit for 30 minutes x 2.0 mA using a left anodal dorsolateral prefrontal cortex montage. Stimulation was paired with physical exercise, online adaptive computerized cognitive training, and guided mindfulness meditation, individualized to each patient, with sessions 3–5 days per week. There was no comparison group; clinical neuropsychological evaluation was completed before and after the intervention, and a symptom inventory based on the full range of PASC symptoms reported in the literature (Assessment of PASC; A-PASC) was developed to measure treatment outcomes. The paper reports that the patients experienced significant improvements across cognitive, emotional, physical, and functional domains, and both returned to work and resumed most of their daily activities following the intervention. Harms, side effects, and withdrawals were not reported. The authors state that tDCS can be delivered as a teleintervention warranting its evaluation as an accessible and scalable treatment option for PASC, and that further study and clinical trials of PASC are warranted. No formal limitations section is stated.
- Combination of transcranial direct current stimulation with online cognitive training improves symptoms of Post-acute Sequelae of COVID-19: A case series.2022 · combination: given with other treatments · 4 in the study
- Transcranial direct current electrical stimulation in combination with aerobic exercise is effective in reducing fatigue and pain in post-COVID-19 systemic autoimmune rheumatic patients2021 · combination: given with other treatments · 9 in the study · preprint
Summary
This single-center, prospective open-label one-arm study asked whether anodal tDCS combined with treadmill aerobic exercise would reduce fatigue and pain in patients with systemic autoimmune rheumatic diseases (SARDs) who had persistent or worsened fatigue or pain for more than 12 weeks after confirmed COVID-19 (post-COVID-19 syndrome). Nine patients were included and started treatment; no comparison group was randomised. Treatment was five daily sessions of anodal tDCS (2 mA, 20 minutes, over C3 or C4 with the cathode at Fp1 or Fp2) given together with treadmill walking for 30 minutes. Patients were assessed within one week before and one week after the protocol, with disease treatments unchanged. After the protocol, pain and fatigue VAS scores decreased significantly (P<0.05). Timed-up-go-test improved 9.5±2.7 vs. 6.8±0.8 (P=0.001) and sit-to-stand test 10.3±3.7 vs. 15.1±4.0 (P=0.037). No changes were observed in FACIT and MFIS fatigue scores and domains, though effect sizes were reported for FACIT and MFIS domains. Exercise intensity did not change (mean 5.5 ± 0.8) and perception of recovery remained unchanged. No subject experienced adverse events; there were no adverse effects of tDCS. One patient (#9) reported worsening of clinical joint symptoms after using tDCS, and patient #8 could not have her final data evaluated because she was in social isolation. Adherence was 100%. The authors state limitations of a limited sample size and lack of a control group.
- Effectiveness of physical, psychological, and alternative interventions for post-COVID-19 condition: a systematic review.2026 · systematic review
Summary
This systematic review asked whether supervised physical, psychological and alternative non-pharmacological treatments help adults with post-COVID-19 condition. It included 27 randomized trials with 1,998 participants; trials were supervised and face-to-face and compared interventions with usual care, placebo/sham or active comparators. Interventions included cardiopulmonary rehabilitation, multimodal and unimodal exercise, CBT and lifestyle programmes, neuromodulation, oxygen therapies, acupuncture and balneotherapy. Intervention durations varied. The review reported that cardiopulmonary rehabilitation and multimodal exercise consistently improved cardiorespiratory fitness and walking capacity; CBT and lifestyle adjustments significantly reduced fatigue and subjective concentration complaints. Examples recorded: in 114 participants, CBT lowered CIS-fatigue by a between-group mean difference of −8.8 points (95% CI −11.9 to −5.8); in 70 participants, active HD-tDCS plus rehabilitation lowered MFIS total fatigue by a between-group difference of −14.03 points (95% CI −20.28 to −7.78). Findings for neuromodulation, complementary and oxygen therapies were heterogeneous, often showing no benefit over placebo. For example, HBOT did not produce significantly greater improvements than sham on any primary or secondary outcome. Side effects and withdrawals were not reported in the recorded data. The authors state that the evidence does not support definitive conclusions about the effectiveness of any intervention category.
- Cognitive Interventions and Rehabilitation to Address Long-COVID Symptoms: A Systematic Review.2026 · systematic review
Summary
This systematic review examined cognitive interventions and rehabilitation for adults with long COVID symptoms. It included 19 articles identified from MEDLINE, CINAHL, PsycINFO, Cochrane Trials, and Scopus, with a search date of July 25, 2023. The review summarized cognitive training, CBT, neurostimulation, combined neurostimulation and cognitive training, and multicomponent rehabilitation programs. Included studies had different designs; the review itself had no comparison group. In a 100-participant randomized trial, an amygdala and insula retraining program was reported to decrease fatigue and increase energy versus control. A 114-participant randomized trial reported CBT reduced fatigue versus care as usual and favored CBT on secondary measures. A 73-participant pre-post study reported higher cognitive scores in all assessed domains after computerized cognitive training. A 64-participant pre-post program reported 42.8% complete recovery and 68% varying improvement in cognitive function, plus significant improvement on the Barthel Index. A 33-participant program reported improved mood, self-efficacy, and participation but no significant fatigue improvement. A 12-participant program reported that all 12 gained insight and 11 reported increased work-life coping. One case report reported short-term memory decreased 15% to 22%. Stopping and side effects were not reported.
- Effectiveness of Non-Pharmacological Interventions for Fatigue in Long COVID: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026 · systematic review
Summary
This systematic review and meta-analysis included 13 RCTs with 1276 participants with long COVID. It compared non-pharmacological interventions—exercise training, cognitive behavioural therapy, non-invasive neuromodulation, and nutritional supplementation—with control conditions. Fatigue severity was assessed with validated instruments. The review reported that exercise training was the only modality associated with a statistically significant reduction in fatigue. For CBT, non-invasive neuromodulation, and nutritional supplementation, the review did not observe a statistically significant pooled effect. The difference in effects between intervention modalities was not statistically significant (p = 0.286). Harms were reported in several trials: two participants discontinued the exercise intervention (transient worsening of fatigue), and 2 participants of the training groups stopped (worsening of their symptoms in response to the intervention). In one trial there were eight AEs (four PEM, two musculoskeletal issues, one nausea and one atypical chest pain) and one unrelated SAE. In another, eight of the sixteen patients receiving active tDCS and nine of the seventeen assigned to sham tDCS experienced mild to moderate side effects such as burning or tingling. The review notes that overall certainty is low to moderate, with substantial between-study heterogeneity and limited RCTs for non-exercise interventions.
- Noninvasive Neuromodulation Techniques in the Recovery of Olfactory Dysfunction in Long COVID: A Systematic Review and Bayesian Meta-Analysis.2026 · systematic review
Summary
This systematic review and Bayesian meta-analysis examined noninvasive neuromodulation for olfactory dysfunction in Long COVID. The search ran through January 22, 2026. A total of four studies were included, using heterogeneous neuromodulation modalities; eligible studies had patients with Long COVID and a control group. The supplied text does not report the number of patients, their location, treatment duration, worsening, or discontinuation. For complete olfactory recovery (normosmia), the pooled RR was 1.59 (95% CrI, 0.41–6.28), with a 73.9% posterior probability of benefit; the CrI included the null value. For clinically meaningful olfactory improvement, the pooled RR was 2.20 (95% CrI, 0.63–7.52), with an 88.8% posterior probability of benefit; the interval marginally included the null value. Sensitivity analyses using wider priors yielded substantially different estimates, indicating prior-dependent results. No serious adverse events were reported across the studies. The authors state that the available evidence suggests a possible favorable direction of effect but that certainty is very low, and they call the findings hypothesis-generating.
- Effects of therapeutic interventions on long COVID: a meta-analysis of randomized controlled trials.2025 · systematic review
Summary
This meta-analysis pooled 51 RCTs with 4026 participants with Long COVID, searching PubMed, Cochrane Library, Embase, Web of Science, SPORTDiscus (EBSCO), CINAHL (EBSCO), and Rehabilitation & Sports medicine source (EBSCO) to July 20, 2025. Trials compared exercise training, respiratory muscle training, telerehabilitation, tDCS, olfactory training, steroid sprays, or PEA-LUT with no intervention, standard primary care, or placebo; follow-up ranged from 14 to 180 days. Outcomes included cardiopulmonary function, exercise capacity, fatigue, dyspnea, and olfactory recovery. Exercise training showed significant better 6MWT (MD 83.20; 95% CI 52.04–114.37) and 30sSTS (MD 3.05; 95% CI 1.96–4.13), but no significant difference for HADS-depression, HADS-anxiety, SF-12-PCS, FVC (% predicted), FEV1, VE/VO2, VE, RER, or FEV1/FVC. Respiratory muscle training showed significant better 6MWT (MD 89.54; 95% CI 9.86–169.23) and MIP (cm H2O) (MD 19.69; 95% CI 10.14–29.24), with no significant difference for FVC, FEV1, MFIS, HADS, or MEP. Telerehabilitation showed significant better 6MWT (MD 34.14; 95% CI 2.54–65.74), 30sSTS (MD 1.41; 95% CI 0.67–2.15), and FSS (MD −1.59; 95% CI −2.64 to −0.53). tDCS showed significant lower MFIS-physical (MD −2.29; 95% CI −4.36 to −0.22). Olfactory training and steroid sprays showed no significant differences; PEA-LUT showed significant higher TDI Score (MD 4.66; 95% CI 2.16–7.15). No side-effect or withdrawal counts were reported; the authors noted exercise may pose a risk of symptom exacerbation in post-exertional malaise. They reported high risk of bias in 33 studies and high heterogeneity.
- Cognitive and Psychological Symptoms in Post-COVID-19 Condition: A Systematic Review of Structural and Functional Neuroimaging, Neurophysiology, and Intervention Studies.2025 · systematic review
Summary
This systematic review asked whether post-COVID-19 condition (PCC) is associated with structural, functional, and neurophysiological brain changes and evaluated noninvasive brain stimulation (NIBS) and cognitive rehabilitation. It included 78 studies with over 5927 individuals, searched in Web of Science, PubMed, and Embase. Treatments were NIBS, including TMS and tDCS, and cognitive rehabilitation/training; comparisons included active versus sham tDCS and rehabilitation versus no rehabilitation. Outcomes covered cognitive and psychological symptoms, fatigue, quality of life, and cognitive test performance. In a randomized tDCS study, 47 participants with PCC were randomized into active (n=23) and sham (n=24) groups; active tDCS significantly reduced physical fatigue immediately posttreatment and at 1-month follow-up and improved depressive symptoms, but no significant effects were seen for cognitive fatigue or overall quality of life. A 4-week randomized trial found a general reduction in fatigue severity over time across both groups, with within-group improvements significant only in the sham condition; no significant between-group differences were observed for fatigue domains, post-COVID symptom burden, anxiety and depressive symptoms, or cognitive function. Mild to moderate side effects such as tingling or burning sensations were reported in both groups and subsided; no persistent adverse effects were noted at follow-up. Cognitive training with tDCS showed greater improvements in cognitive and psychosocial fatigue, anxiety, and quality of life. Dual-task augmented reality rehabilitation improved cognitive performance in 10 participants compared with 10 who did not receive rehabilitation, with no significant differences for fatigue severity, cardiovascular endurance, or muscular fatigue. TMS studies reported improvements in depression, insomnia, anxiety, neuropsychiatric symptoms, apathy, and fatigue, while a double-blind trial found no significant changes in cognitive test outcomes. Stopping or worsening was not reported. The authors state limitations include heterogeneity and small numbers of high-quality randomized controlled trials.
- Non-Invasive Brain Stimulation for Post-COVID-19 Conditions: A Systematic Review.2025 · systematic review
Summary
This systematic review asked whether non-invasive or minimally invasive brain stimulation reduces symptoms of post-COVID-19 condition. Four databases were searched through April 2nd, 2024; 19 studies were included, covering tDCS, TMS, tVNS and toACS. Across the included studies, Klirová et al. (33 patients) found no significant intergroup difference in post-COVID-19 symptoms. Santana et al. (70 patients) reported a significant reduction in fatigue and anxiety and an improvement in quality of life with active HD-tDCS compared with sham. Oliver-Mas et al. (47 patients) reported a significant improvement of physical fatigue and depressive symptoms in the active tDCS group compared with sham. Gracia et al. (15 patients) found no significant improvement across groups. Vestito et al. (7 patients) reported a significant improvement of hyposmia comparing tDCS with sham. Sakib et al. (4 patients) detected no significant group differences for rTMS. Badran et al. (13 patients) reported a trend towards mild to moderate effects of tVNS on fatigue. Reported harms included transient burning or tingling during tDCS, mild and transient headache and dizziness, transient tingling on the scalp, transient mild skin irritation with tVNS, and transient pain at the TMS stimulation site. The authors state that sample sizes are small, many studies are case reports, randomization and control groups are often missing, and diagnostic criteria differ.
- Systematic review of interventions for mental health, cognition and psychological well-being in long COVID.2024 · systematic review
Summary
This systematic review aimed to identify and synthesise publicly available research testing treatments for mental health, cognition and psychological well-being in long COVID. It included 33 documents representing 31 studies and 2477 participants recruited across four continents. The studies covered 7 psychosocial, 5 pharmaceutical, 3 natural supplement, 9 neurocognitive, 2 physical rehabilitation and 5 integrated intervention studies; 11 were RCTs, 2 non-randomised controlled trials, 10 uncontrolled trials, 7 case studies or series and 1 qualitative study. Some controlled trials reported significant group×time interactions: vortioxetine for depression and health-related QoL but not cognition; hyperbaric oxygen for total cognition and psychological distress only; high-definition transcranial direct current stimulation for cognitive and psychosocial fatigue, anxiety and QoL; and a programme combining non-invasive cognitive stimulation and guided mindfulness for mental fatigue, anxiety, depression, mood disturbance and several cognitive domains. Other trials reported no significant group×time interaction, including an adaptogen formulation and the ReCOVERY app. Many uncontrolled studies reported significant prepost improvements, but the authors state these cannot be definitively associated with treatment without a control group. Counts of people who worsened or stopped and side-effect counts were not reported in the recorded data; the authors note many studies did not report adverse events.
- Research evidence on the management of the cognitive impairment component of the post-COVID condition: a qualitative systematic review.2024 · systematic review
Summary
This qualitative systematic review asked which treatments have been studied for cognitive impairment after COVID-19. The search covered PubMed, Scopus, and ProQuest up to December 31, 2023, and included 29 studies of post-COVID cognitive impairment; samples ranged from single patients to larger groups. Treatments included cognitive remediation, multidisciplinary rehabilitation, noninvasive brain stimulation, hyperbaric oxygen, pharmacological and nutraceutical agents, neurofeedback, photobiomodulation, and meditation. Comparisons, where reported, included control, sham, placebo, or usual-care groups. Cognitive functioning was assessed with standardized tests, test batteries, or structured interviews. Findings varied. A randomized sham-controlled HBOT trial in 37 subjects reported significant improvements in global cognitive functioning, attention, and executive functions versus control. A famotidine RCT reported significantly improved global cognition in the treatment group (N = 25). A donepezil RCT found no differences between N = 15 and N = 10 in memory after 4 and 12 weeks. A tDCS randomized sham-controlled trial in 23 subjects found no significant effects on executive functioning and processing speed after eight tDCS sessions. A remote multidisciplinary RCT found no significant differences between N = 52 and N = 48. A multidisciplinary study in 80 subjects found no significant improvements in memory and attention at discharge. Other studies reported improvements in smaller or uncontrolled samples. No worsening, stopping, or side effects were reported in the recorded data. The authors state limitations including heterogeneity, lack of long-term follow-up, and under-characterization of samples.
- Interventions for the management of long covid (post-covid condition): living systematic review.2024 · systematic review
Summary
This living systematic review assessed drug and non-drug interventions for long covid in adults. It included 24 unique trials with 3695 patients, predominantly from the Americas or Europe. One trial (n=114) compared an online CBT programme called “fit after covid” with usual care; moderate certainty evidence suggested CBT probably reduces fatigue (mean difference −8.4, 95% CI −13.11 to −3.69) and probably improves concentration (mean difference −5.2, −7.97 to −2.43). One trial (n=585) compared combined physical and mental health rehabilitation with one session of online advice and support; moderate certainty evidence suggested it probably increases recovery or important improvement (161 more per 1000 patients, 95% CI 61 more to 292 more), improves quality of life (mean difference 0.04, 95% CI 0.00 to 0.08), and reduces depression (mean difference −1.50, −2.41 to −0.59), with little or no effect on physical and cognitive function or anxiety. Intermittent aerobic exercise 3-5 times weekly for 4-6 weeks probably improves physical function compared with continuous exercise (mean difference 3.8, 95% CI 1.12 to 6.48; n=110). Vortioxetine for eight weeks did not improve cognitive function; coenzyme Q10 500 mg/day for six weeks probably did not improve quality of life (n=119); SIM01 might alleviate fatigue (200 more per 1000 patients, 95% CI 94 more to 336 more; n=463) but probably did not improve quality of life. No instances of post-exertional malaise were reported in the rehabilitation trial; effects on serious adverse events were very uncertain.
- Intervention modalities for brain fog caused by long-COVID: systematic review of the literature.2024 · systematic review
Summary
This systematic review examined interventions for brain fog caused by long-COVID in adults with proven symptoms. It included 17 studies, including a case report of 1 patient and a cohort of 208. Interventions were rehabilitation (cognitive training, telerehabilitation, mindfulness-based programs), noninvasive brain stimulation (transcranial magnetic, direct current, alternating current stimulation, photobiomodulation), hyperbaric oxygen therapy, and PEA-LUT. Treatment duration varied; PEA-LUT was assessed three months after treatment. Some studies compared an intervention with control or treatment as usual, while others reported before-and-after changes. Outcomes included MoCA, MMSE, WAIS4, BNIS, NeuroTrax, CANTAB, TAP/AVLT, CAB, PEBL, and PDQ-D-5. Noninvasive brain stimulation studies all showed improvement in cognitive ability. Hyperbaric oxygen studies showed improvements in cognitive tests and brain perfusion. PEA-LUT improved PRMQ and MoCA scores in treated patients; in one trial mental clouding fell in groups 1 and 3 but not group 2. Rehabilitation results were mixed, with some studies reporting enhancement and others no significant improvement. Adverse effects were mild: scalp pain in 4 out of 23 patients after stimulation; after hyperbaric oxygen, barotrauma n=4, ear pain n=1, palpitations n=3, headache n=1, fever n=1. Rehabilitation and pharmacological treatment had no adverse effects. The authors state limitations include a limited number of studies and high heterogeneity.
- Transcranial stimulation as a possible therapeutic proposal in long COVID.2026 · review
Summary
This critical review examined evidence on neuromodulation for long COVID; it reports no new study participants. It summarized named trials and cases. Santana et al. (2023) enrolled 70 patients with post-COVID fatigue and reported significantly reduced fatigue on the MFIS with HD-tDCS versus sham. Andrade et al. (2022) studied 56 adults after mechanical ventilation and reported significantly increased ventilator-free days in the first 28 days versus controls. Oliver-Mas et al. (2023) studied 47 post-COVID patients with persistent fatigue; active tDCS significantly reduced physical fatigue immediately and at 1-month follow-up and reduced depressive symptoms, while cognitive fatigue and quality of life did not show significant improvements. In Oliver-Mas et al. (2025), M1 stimulation showed slight superiority for fatigue and sleep. Vidal et al. (2025) reported modest but significant improvements in inhibitory control, processing speed, and divided attention. Klírová et al. (2024) found no significant improvement in cognitive function. Souza et al. (2024) reported respiratory improvements in six patients; Gómez et al. (2021) reported reduced HARS, HDRS, and MFIS scores in a 58-year-old patient. A cited meta-analysis of 51 randomized trials with 4,026 participants reported improved functional capacity and reduced dyspnea and fatigue, but no consistent effects on spirometric parameters, global fatigue, or anxiety and depression. Adverse effects in Oliver-Mas et al. (2023) were mild; the review states adverse events were limited to mild and transient skin discomfort.
- Digital Interventions Addressing Cognitive and Psychological Symptoms in Long COVID: Scoping Review of Multicomponent Approaches.2026 · review
Summary
This scoping review examined digital interventions for cognitive and psychological symptoms in people with long COVID. It included 25 (2.82%) records identified through a database search between December 2024 and February 2025. The records covered telehealth or telerehabilitation, virtual reality, mobile health apps, online psychological therapies, game-based cognitive training, neuromodulation (transcranial direct current stimulation), and multicomponent programs. No comparison was required for inclusion; comparators were reported when present. Outcomes concerned attention, memory, executive function, depression, anxiety, fatigue, and well-being. Reported effects were mixed. Telehealth or telerehabilitation records were summarized as improvements in quality of life, mental health (anxiety and depression), and self-efficacy, with mixed effects on cognition. Virtual reality records were summarized as enhanced emotional well-being and physical functioning, inconsistent effects on cognition, and some usability issues; some users reported side effects such as dizziness and headaches. Mobile health app records were summarized as gains in attention, mood, and self-reported recovery. Online psychological therapy records were summarized as decreased anxiety, posttraumatic stress disorder, and depression and high feasibility and acceptability. Game-based cognitive training was summarized as improved processing speed and task-switching and no sustained improvement in attention. Neuromodulation was summarized as enhanced cognition, mood, and energy levels in a small-scale pilot study. Multicomponent programs were summarized as broad improvements across mental health, cognitive symptoms, and physical activity. The authors state limitations including small sample sizes, lack of control groups, heterogeneity in outcomes and intervention protocols, and short follow-up durations, plus underrepresentation of older adults and underserved populations.
- CLINICAL ASPECTS OF NEUROLOGICAL MANIFESTATIONS OF LONG COVID AND PROSPECTS FOR PHYSIOTHERAPEUTIC INTERVENTIONS (REVIEW OF LITERATURE)2025 · review
Summary
This literature review examined neurological and neuropsychiatric manifestations of Long COVID and possible physiotherapeutic interventions. It did not report its own patient cohort; it summarized published reports on pulsed electromagnetic field (PEMF) therapy and repetitive transcranial magnetic stimulation (rTMS), including tDCS and TMS. For PEMF, a cited pilot randomized trial reported improvements in functional capacity and quality of life versus placebo; no serious adverse events were noted. A cited clinical observation described immediate improvement in neuromuscular interaction and sustained benefit over six months. For rTMS, a Japanese case series (n>20) suggested reduced depressive symptoms and enhanced cognitive function. A 2023 series documented reductions in chronic fatigue and cognitive slowing. A 2024 pilot (n=4) reported good tolerability and short-term cognitive gains, and single-case reports associated 10 iTBS sessions with mood/cognitive improvements. A cited systematic review of 19 studies found tDCS and TMS as potential modalities but highly inconsistent findings. Harms included transient local sensations during PEMF sessions and transient scalp tingling or headache with TMS; serious adverse events were not reported. The authors stated the evidence base is underpowered pilot data and case series, utility is unproven, and larger randomized trials with standardized protocols are needed.
- Interventions for Long COVID: A Narrative Review.2025 · review
Summary
This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).
- Brain stimulation as a therapy in Long-Covid: A Narrative Review2025 · review
Summary
This narrative review examined noninvasive brain stimulation therapies as possible treatments for long-COVID syndrome, which the authors describe as prevalent among people infected by the virus and without a defined treatment. The authors note that long-COVID is heterogeneous and triggers different symptoms in each patient, with fatigue, cognitive dysfunction, anxiety and depression most frequently reported. They focus on transcranial magnetic stimulation (TMS), while also discussing transcranial direct current stimulation and transcutaneous vagus nerve stimulation. The abstract does not report the number of participants, the number of studies included, a comparison group, randomisation, treatment duration, or follow-up. The authors state that the results of the different studies carried out so far, which have used transcranial direct current stimulation, transcutaneous vagus nerve stimulation or TMS, have shown that these techniques can be effective in treating the clinical symptoms caused by post-COVID syndrome. They conclude that more studies are needed to evaluate this type of therapy on these symptoms, and they state that the great heterogeneity of this syndrome represents a great challenge for public health and a significant socioeconomic cost, requiring investment in the study of new treatment approaches. No side effects, withdrawals, or worsening were reported in the abstract. The abstract does not report patient ratings of treatment.
- Effects of transcranial direct current stimulation on COVID-19 neurological symptoms: a mini-review2023 · review
Summary
This mini-review searched MEDLINE via PubMed and Cochrane databases for long COVID and non-invasive brain stimulation and included two case-report articles on tDCS. The cases were a 58-yearold man and two referred female participants with long COVID and cognitive symptoms. Gómez et al. (2021) described daily tDCS; after the final session, his HARS, HDRS, and MFIS scores showed a clinically significant decline from the initial session, and he reported feeling better, worrying less, and improvements in anxiety symptoms and cognitive and physical functioning. Eilam-Stock et al. (2021) described a remotely supervised tDCS protocol paired with physical exercise, online adaptive computerized cognitive training, and guided mindfulness meditation; both participants reported improvement across physical, cognitive, emotional, and functional domains. The review states no control groups were used, the studies had methodological differences, and the sample size is insufficient to draw definitive conclusions. Side effects and withdrawals were not reported. The authors conclude that more data are needed on efficacy and optimal implementation and that randomized trials compared with sham stimulation might help.
- Treatable traits for long COVID.2023 · review
Summary
This comprehensive review asked how a treatable traits approach could be applied to long COVID. It combined an umbrella review of 22 systematic reviews identifying long COVID symptoms and complications with a systematic review of 18 randomized controlled trials of prevention or management. The trials tested many interventions, including metformin for 14 days during acute COVID-19 versus placebo, hyperbaric oxygen therapy versus sham, exercise training or respiratory muscle training versus usual care or sham, HD-tDCS versus sham, L-arginine plus liposomal vitamin C versus placebo, aromatherapy versus inert oils, and platelet-rich plasma injections versus saline. Outcomes included long COVID incidence, cognition, olfaction, dyspnoea, fatigue, exercise capacity and health-related quality of life. In one prevention trial, metformin was associated with reduced long COVID incidence at 10 months (hazard ratio 0.58 [95% CI 0.38, 0.88]) among 564 metformin and 561 placebo participants; ivermectin and fluvoxamine showed no significant benefit. For management, hyperbaric oxygen improved cognition compared with sham (104.1 ± 7.2 versus 101.3 ± 8.9, p = 0.038), and exercise training improved exercise capacity compared with exercise advice (38.9 ± 10.8 versus 36.1 ± 9.5 mL/kg/min, p = 0.035). Some studies found no significant between-group differences, including a larger exercise trial. Adverse events included 13 during hyperbaric oxygen versus 14 during control; one aromatherapy participant withdrew on day 13 with headaches, and one sham IMT participant withdrew for symptom exacerbation. The authors state the review was limited by not conducting a meta-analysis and by heterogeneity of the included systematic reviews.
- The therapeutic potential of non-invasive brain stimulation for the treatment of Long-COVID-related cognitive fatigue.2022 · review
Summary
This review examined Long-COVID-related fatigue, with a focus on cognitive fatigue, and discussed non-invasive brain stimulation as a possible treatment approach. It was a review article with no comparison group, randomisation, or crossover. The review includes data before August 2022, covering the first two and a half years of COVID-19 research and approximately the first two years of Long-COVID research; it reported no enrolled, analysed, or follow-up numbers for itself. For Long-COVID, Gómez et al. administered 20 repetitive frontal tDCS stimulations in one Long-COVID patient and reported a clinically meaningful reduction in subjective trait fatigue ratings by 50 points; the patient felt less anxiety and showed improved cognitive performance. Eilam-Stock et al. reported two Long-COVID patients given repetitive, at-home frontal tDCS stimulations; Patient 1 reported significant improvements in fatigue perception, it remained stable in Patient 2, and both returned to their job after treatment and resumed most of their prior activities. Badran et al. investigated repetitive, at-home taVNS in people with Long-COVID and showed a positive mild to moderate effect on mental fatigue in a subset of individuals. The review also described tDCS findings in MS and gamma-tACS in healthy subjects, and mentioned Amantadine and Modafinil as off-label options for fatigue in MS with inconsistent results. The authors caution that positive NIBS effects in healthy and clinical subgroups may not translate to LCOF and that LCOF overlaps CFS-related fatigue. No side-effect or withdrawal counts were recorded for the reviewed Long-COVID reports.